DNIB Unwind, Inc.
(Other OTC/NBB : BIND)

( )
BIND After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 2.91%69.000.0%$1792.09m
GILDGilead Sciences, Inc. -0.22%73.341.0%$1310.05m
AMGNAmgen, Inc. 0.73%226.431.3%$654.36m
REGNRegeneron Pharmaceuticals, Inc. 1.59%569.912.5%$571.28m
NVAXNovavax, Inc. -7.91%46.11102.0%$561.17m
VRTXVertex Pharmaceuticals, Inc. 0.12%284.961.9%$530.07m
BIIBBiogen, Inc. 0.02%304.531.6%$421.31m
ILMNIllumina, Inc. 1.51%354.703.5%$346.79m
SRNESorrento Therapeutics, Inc. 0.80%5.071.8%$295.47m
SGENSeattle Genetics, Inc. 1.02%155.776.1%$235.46m
ALXNAlexion Pharmaceuticals, Inc. 0.36%101.502.0%$221.68m
MGNXMacroGenics, Inc. 0.84%25.376.2%$199.40m
CODXCo-Diagnostics, Inc. 2.94%18.550.0%$198.21m
AAgilent Technologies, Inc. 5.24%84.981.6%$189.94m
BMRNBioMarin Pharmaceutical, Inc. 2.80%97.514.3%$148.95m

Company Profile

They are a clinical-stage nanomedicine platform company developing Accurinsâ„¢, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.